Screener
Xeris Biopharma Holdings, Inc. XERS Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
FAQ
- What is Xeris Biopharma Holdings, Inc.'s accounts payable?
- Xeris Biopharma Holdings, Inc. (XERS) reported accounts payable of $9.34M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s accounts payable changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s accounts payable decreased by 1.3% year-over-year, from $9.46M to $9.34M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s accounts payable has grown at a -0.3% compound annual growth rate (CAGR), from $3.12M to $3.08M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Xeris Biopharma Holdings, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude